Evusheld significantly reduced risk of severe COVID-19 or death in TACKLE Phase III treatment trial
DEP® ADCs exploit the unique potential of Starpharma's DEP® technology to provide enhanced characteristics to ADCs i
The partnership will accelerate stockpiling, channel distribution and hospital access for the amubarvimab/romlusevimab combination in China
AbTis will have access to WuXi XDC's integrated services for linker and payload manufacturing
Shanghai Public Health Clinical Center Completed the First Patient Dosing in Clinical Study of PD-L1 Antibody ASC22 in Combination with Chidamide for Functional Cure of HIV Infection
New milestone in the establishment of super-trillion antibody libraries for antibody discovery of challenging targets
The new IGX-Track App adds seamless analysis of antibody panning campaigns to the IGX Platform
Companies to leverage proprietary IgM antibody technology platform to discover agonists against three oncology targets and three immunology/inflammation targets
It also empowers domestic precision immunotherapy for tumours and promotes the high-quality development of China's biopharmaceutical industry
Jointly fund and develop up to three antibody-drug conjugate programs for the treatment of cancer
Subscribe To Our Newsletter & Stay Updated
